RBC Capital Initiates Coverage On Jasper Therapeutics with Outperform Rating, Announces Price Target of $70
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with an Outperform rating and a price target of $70.

March 28, 2024 | 8:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has initiated coverage on Jasper Therapeutics with an Outperform rating and a price target of $70.
Analyst ratings, especially from reputable firms like RBC Capital, can significantly influence investor sentiment and stock prices. An Outperform rating combined with a high price target suggests a strong bullish outlook for Jasper Therapeutics, likely leading to increased investor interest and potentially a rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100